Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.

Eisaku Miyauchi,Satoshi Morita,Atsushi Nakamura,Yukio Hosomi,Kana Watanabe,Satoshi Ikeda,Masahiro Seike,Yuka Fujita,Koichi Minato,Ryo Ko,Toshiyuki Harada,Koichi Hagiwara,Kunihiko Kobayashi,Toshihiro Nukiwa,Akira Inoue

Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.

2021

Eisaku Miyauchi
Satoshi Morita
Atsushi Nakamura
Yukio Hosomi
Kana Watanabe
Satoshi Ikeda
Masahiro Seike
Yuka Fujita
Koichi Minato
Ryo Ko
Toshiyuki Harada
Koichi Hagiwara
Kunihiko Kobayashi
Toshihiro Nukiwa
Akira Inoue

9081Background: NEJ009 study is the first randomized phase III trial that compared gefitinib plus chemotherapy with gefitinib in patients with untreated NSCLC harboring EGFR mutations. We report an...

Keywords:

non small cell
Medicine
Lung cancer
Chemotherapy
in patient
Cancer research
Gefitinib
egfr mutation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations